MAPT and Cognitive impairment: We observed that intraventricular Aβ1-42 peptide administration induced AD-like changes, including significant cognitive impairment as well as substantial neuronal loss, tau pathology, β-amyloid pathology, downregulation of synaptogenesis and gliosis in the prefrontal cortex and hippocampus of rats.